Paragonix to Unveil Clinical Data on Organ Preservation at ISHLT 2026 — Paragonix Technologies, Inc.

Event summary

Paragonix will present 11 clinical studies on heart and lung preservation at ISHLT 2026 (April 22-25).
Research compares controlled hypothermic preservation vs. normothermic methods for transplant outcomes.
Symposiums will focus on lung and heart preservation innovations and measurable impacts.
Data comes from multi-center GUARDIAN Clinical Registries involving real-world patient outcomes.

The big picture

Paragonix's presentation at ISHLT 2026 comes as organ preservation technology gains traction amid global transplant shortages. The company, now part of Getinge, is positioning itself as a leader in hypothermic preservation, challenging normothermic perfusion methods. Success in demonstrating cost and outcome benefits could accelerate adoption in transplant centers worldwide.

What we're watching

Clinical Validation: Whether Paragonix can demonstrate superior outcomes for controlled hypothermic preservation compared to competing methods.
Market Expansion: The pace at which Paragonix extends its technology into pediatric and extended criteria donor transplants.
Regulatory Advantage: How FDA-cleared and CE-marked status will affect adoption rates in different global markets.